Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 15/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10062561 | 0.76 | LTA4H (0.63) | LTA4HCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL27876154 | 0.75 | LTA4H (0.55) | LTA4HCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8639571 | 0.75 | LTA4H (0.44) | LTA4HCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8641926 | 0.73 | LTA4H (0.44) | LTA4HS1PR1S1PR3 | |
| SCHEMBL7440978 | 0.73 | L3MBTL1 (0.69) | LTA4HCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1912758 | 0.72 | LTA4H (0.71) | LTA4HCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL9617469 | 0.72 | LTA4H (0.57) | LTA4HCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL930342 | 0.72 | NQO1 (0.33) | — | |
| SCHEMBL570564 | 0.70 | L3MBTL1 (0.70) | LTA4HCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL11844142 | 0.70 | RXRA (0.60) | LTA4HCYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424500-A1 | LIPID FORMULATION OF APOPTOSIS PROMOTER | Abbott Laboratories (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20120022121-A1 | INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-01-26 | — | — | US | disclosed |
| WO-2010127198-A1 | FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127192-A1 | LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | disclosed |
| EP-2038252-A2 | SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF | University of Tennessee Research Foundation (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008008433-A2 | SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2008-01-17 | — | — | WO | disclosed |
| EP-1539123-A1 | USE OF A COMBINATION OF DPPE WITH OTHER CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF BREAST CANCER | The University of Manitoba (CA) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024131-A1 | USE OF A COMBINATION OF DPPE WITH OTHER CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF BREAST CANCER | THE UNIVERSITY OF MANITOBA (CA) | 2004-03-25 | — | — | WO | disclosed |
| EP-0737067-A1 | METHOD OF TREATMENT OF HORMONE-UNRESPONSIVE METASTATIC PROSTATE CANCER | UNIVERSITY OF MANITOBA (CA) | 1996-10-16 | — | — | EP | disclosed |
| EP-0684817-A1 | CANCER TREATMENT | UNIVERSITY OF MANITOBA (CA) | 1995-12-06 | — | — | EP | disclosed |
| WO-1995017887-A1 | METHOD OF TREATMENT OF HORMONE-UNRESPONSIVE METASTATIC PROSTATE CANCER | UNIVERSITY OF MANITOBA (CA) | 1995-07-06 | — | — | WO | disclosed |
| WO-1994018961-A1 | CANCER TREATMENT | UNIVERSITY OF MANITOBA (CA) | 1994-09-01 | — | — | WO | disclosed |
| EP-0563127-A1 | IMPROVED TREATMENT METHOD FOR CANCER. | UNIV MANITOBA (CA) | 1993-10-06 | — | — | EP | disclosed |
| WO-1992011035-A1 | IMPROVED TREATMENT METHOD FOR CANCER | UNIVERSITY OF MANITOBA (CA) | 1992-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022121-A1 | INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR | TUBB, TUBB3, TUBB1 | LTA4H 1688/4885CYP1A2 3744/4885CYP2D6 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.